PL415351A1 - Sposób namnażania in vitro komórek T regulatorowych (Treg) - Google Patents

Sposób namnażania in vitro komórek T regulatorowych (Treg)

Info

Publication number
PL415351A1
PL415351A1 PL415351A PL41535115A PL415351A1 PL 415351 A1 PL415351 A1 PL 415351A1 PL 415351 A PL415351 A PL 415351A PL 41535115 A PL41535115 A PL 41535115A PL 415351 A1 PL415351 A1 PL 415351A1
Authority
PL
Poland
Prior art keywords
cells
tregs
regulatory
treg
vitro propagation
Prior art date
Application number
PL415351A
Other languages
English (en)
Other versions
PL236046B1 (pl
Inventor
Natalia Marek-Trzonkowska
Piotr Trzonkowski
Małgorzata Myśliwiec
Original Assignee
Gdański Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gdański Uniwersytet Medyczny filed Critical Gdański Uniwersytet Medyczny
Priority to PL415351A priority Critical patent/PL236046B1/pl
Priority to SM20260185T priority patent/SMT202600185T1/it
Priority to FIEP16834056.0T priority patent/FI3402877T3/fi
Priority to DK16834056.0T priority patent/DK3402877T3/da
Priority to PT168340560T priority patent/PT3402877T/pt
Priority to LTEPPCT/PL2016/000152T priority patent/LT3402877T/lt
Priority to PCT/PL2016/000152 priority patent/WO2017105265A1/en
Priority to EP16834056.0A priority patent/EP3402877B1/en
Priority to RS20260241A priority patent/RS67800B1/sr
Priority to ES16834056T priority patent/ES3062934T3/es
Priority to US16/063,144 priority patent/US11072779B2/en
Publication of PL415351A1 publication Critical patent/PL415351A1/pl
Publication of PL236046B1 publication Critical patent/PL236046B1/pl
Priority to US17/381,192 priority patent/US20210348126A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/48—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Przedmiotem zgłoszenia jest nowy sposób namnażania in wtro komórek Treg CD4+CD25HighCD127-/LowFoxP3+, gdzie: proces namnażania komórek Treg odbywa się przez cały czas lub okresowo w temperaturze poniżej 37°C, optymalnie w temperaturze 33°C, wyizolowane komórki Treg namnaża się w pożywce SCGM lub X-vivo-20 suplementowanej ludzką surowicą lub płodową surowicą bydlęcą, do hodowli dodawane są mikrosfery magnetyczne opłaszczone przeciwciałami anty-CD3 i anty-CD28 w stosunku 1 : 1 (komórka: mikrosfera) oraz interleukina 2.
PL415351A 2015-12-17 2015-12-17 Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+ PL236046B1 (pl)

Priority Applications (12)

Application Number Priority Date Filing Date Title
PL415351A PL236046B1 (pl) 2015-12-17 2015-12-17 Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+
LTEPPCT/PL2016/000152T LT3402877T (lt) 2015-12-17 2016-12-19 Reguliacinių t ląstelių ex vivo dauginimo būdas
FIEP16834056.0T FI3402877T3 (fi) 2015-12-17 2016-12-19 Menetelmä säätelevien T-solujen lisäämiseksi ex vivo
DK16834056.0T DK3402877T3 (da) 2015-12-17 2016-12-19 Metode til ex vivo-ekspansion af regulerende t-celler
PT168340560T PT3402877T (pt) 2015-12-17 2016-12-19 Método para expansão ex vivo de células t reguladoras
SM20260185T SMT202600185T1 (it) 2015-12-17 2016-12-19 Metodo per l’espansione ex vivo di cellule t regolatorie
PCT/PL2016/000152 WO2017105265A1 (en) 2015-12-17 2016-12-19 Method for ex vivo expansion of regulatory t cells
EP16834056.0A EP3402877B1 (en) 2015-12-17 2016-12-19 Method for ex vivo expansion of regulatory t cells
RS20260241A RS67800B1 (sr) 2015-12-17 2016-12-19 Postupak za ex vivo ekspanziju regulatornih t ćelija
ES16834056T ES3062934T3 (en) 2015-12-17 2016-12-19 Method for ex vivo expansion of regulatory t cells
US16/063,144 US11072779B2 (en) 2015-12-17 2016-12-19 Method for ex vivo expansion of regulatory T cells
US17/381,192 US20210348126A1 (en) 2015-12-17 2021-07-21 Method for ex vivo expansion of regulatory t cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL415351A PL236046B1 (pl) 2015-12-17 2015-12-17 Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+

Publications (2)

Publication Number Publication Date
PL415351A1 true PL415351A1 (pl) 2017-06-19
PL236046B1 PL236046B1 (pl) 2020-11-30

Family

ID=57960799

Family Applications (1)

Application Number Title Priority Date Filing Date
PL415351A PL236046B1 (pl) 2015-12-17 2015-12-17 Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+

Country Status (11)

Country Link
US (1) US11072779B2 (pl)
EP (1) EP3402877B1 (pl)
DK (1) DK3402877T3 (pl)
ES (1) ES3062934T3 (pl)
FI (1) FI3402877T3 (pl)
LT (1) LT3402877T (pl)
PL (1) PL236046B1 (pl)
PT (1) PT3402877T (pl)
RS (1) RS67800B1 (pl)
SM (1) SMT202600185T1 (pl)
WO (1) WO2017105265A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11384336B2 (en) 2016-12-07 2022-07-12 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory T cells
PL241050B1 (pl) * 2019-12-12 2022-07-25 Gdanski Univ Medyczny Zastosowanie limfocytów T regulatorowych jako leku w leczeniu stwardnienia rozsianego
CN113564117B (zh) * 2021-08-23 2023-12-26 山东省齐鲁干细胞工程有限公司 一种冻存脐带血来源调节性t细胞体外扩增优化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1953767B (zh) * 2004-01-08 2011-03-16 加利福尼亚大学董事会 调节t细胞抑制自身免疫
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
JP5937003B2 (ja) 2009-05-18 2016-06-22 セラコス・インコーポレイテッドＴｈｅｒａｋｏｓ， Ｉｎｃ． 免疫介在性疾患における臨床応用のための、抑制機能の高められた制御性ｔ細胞のエクスビボ増加方法
WO2013050596A1 (en) 2011-10-06 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of maintaining foxp3 expression in expanded t regulatory cell
EP2804625A4 (en) 2012-01-17 2015-10-28 Univ Northeastern METHOD AND COMPOSITIONS FOR THE EXPANSION OF IMMUNOSUPPRESSIVE REGULATORY T CELLS IN VITRO AND USES THEREOF
PL218400B1 (pl) 2012-06-06 2014-11-28 Gdański Univ Medyczny Szczepionka do leczenia cukrzycy typu 1 u dzieci, zastosowanie sortera komórek oraz sposób namnażania komórek Treg in vitro do wytwarzania szczepionki do leczenia cukrzycy typu 1

Also Published As

Publication number Publication date
PT3402877T (pt) 2026-03-03
PL236046B1 (pl) 2020-11-30
ES3062934T3 (en) 2026-04-14
EP3402877A1 (en) 2018-11-21
SMT202600185T1 (it) 2026-05-12
RS67800B1 (sr) 2026-03-31
WO2017105265A1 (en) 2017-06-22
DK3402877T3 (da) 2026-02-23
EP3402877B1 (en) 2025-11-26
FI3402877T3 (fi) 2026-02-11
LT3402877T (lt) 2026-03-10
US20180362928A1 (en) 2018-12-20
US11072779B2 (en) 2021-07-27

Similar Documents

Publication Publication Date Title
Putnam et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation
Bahri et al. Ectonucleotidase CD38 demarcates regulatory, memory-like CD8+ T cells with IFN-γ-mediated suppressor activities
Dwyer et al. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype
BR112020016176A2 (pt) Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
Taflin et al. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions
Akimova et al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs
Zhou et al. Isolated CD39 expression on CD4+ T cells denotes both regulatory and memory populations
Forget et al. Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma
EA202091407A1 (ru) Состав бессывороточной среды для культивирования клеток и способы его применения
Kobyzeva et al. CD56dimCD57− NKG2C+ NK cells retaining proliferative potential are possible precursors of CD57+ NKG2C+ memory-like NK cells
Parodi et al. CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes
Onoda et al. Human CD4+ central and effector memory T cells produce IL-21: effect on cytokine-driven proliferation of CD4+ T cell subsets
MX2019010583A (es) Anticuerpos contra ligando 1 de muerte programada.
MY180750A (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
MA39867A (fr) Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
NZ725201A (en) Improved methods for manufacturing adoptive cell therapies
Sato et al. Impact of culture medium on the expansion of T cells for immunotherapy
EP4289944A3 (en) Method for preparing genetically-modified t cells which express chimeric antigen receptor
Moreira-Teixeira et al. Rapamycin combined with TGF-β converts human invariant NKT cells into suppressive Foxp3+ regulatory cells
EP4458419A3 (en) Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
Lu et al. iTreg induced from CD39+ naive T cells demonstrate enhanced proliferate and suppressive ability
CY1123467T1 (el) Θεραπευτικο εμβολιο για τη θεραπεια του παιδικου διαβητη τυπου 1, εφαρμογη του κυτταροδιαχωριστη κυτταρομετριας ροης και της μεθοδου πολλαπλασιασμου των κυτταρων treg για την παραγωγη θεραπευτικου εμβολιου για τη θεραπεια του διαβητη τυπου 1
SA522432641B1 (ar) T تركيبة لزراعة الخلية التنظيمية واستخدامها
Grinnemo et al. Immunomodulatory effects of interferon-γ on human fetal cardiac mesenchymal stromal cells
Arteaga-Cruz et al. Highly purified and functionally stable in vitro expanded allospecific Tr1 cells expressing immunosuppressive graft-homing receptors as new candidates for cell therapy in solid organ transplantation